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Abstract For trials of user-dependent HIV prevention
products, accurate adherence measurements are essential to
interpret and compare results across trials. We used pill
count data from two recent HIV prevention trials of herpes
simplex virus type 2 (HSV-2) suppression, to show that
estimates of adherence vary substantially depending on
assumptions that are made in analysing pill count data. We
associate calculated adherence with biological markers of
anti-HSV-2 activity. In both trials, calculated adherence
varied considerably, depending on the summary measure
used, and the handling of intervals with apparent ‘over-
adherence’ (fewer pills returned than expected), and
unreturned pills. Intervals of apparent over-adherence were
associated with reduced antiviral effects on biological
markers of herpes reactivation, indicating these are likely
to represent periods of non-adherence. Our results
demonstrate the clear need for standardisation in reporting
of adherence data that are based on pill counts.
Keywords Adherence  HIV prevention  Pill counts
Introduction
Novel, user-dependent, biomedical HIV prevention inter-
ventions require high adherence to achieve efficacy, as
demonstrated in clinical trials of tenofovir gel [1, 2], daily
oral antiretroviral (ARV) pre-exposure prophylaxis (PrEP)
[2–6], and ARVs taken by HIV-positive persons to prevent
transmission [7]. For such user-dependent methods, with
dosing either at fixed intervals or linked to specific events
(such as sex acts), accurate and objective measurements of
adherence are critical for understanding trial results, since
K. Baisley (&)  R. Hayes
Department of Infectious Disease Epidemiology, London School
of Hygiene and Tropical Medicine, London, UK
e-mail: kathy.baisley@lshtm.ac.uk
J. M. Baeten  D. J. Donnell  C. Celum
Department of Global Health, University of Washington,
Seattle, WA, USA
J. M. Baeten  C. Celum
Department of Medicine, University of Washington, Seattle,
WA, USA
J. M. Baeten  C. Celum
Department of Epidemiology, University of Washington,
Seattle, WA, USA
J. P. Hughes
Department of Biostatistics, University of Washington,
Seattle, WA, USA
D. J. Donnell
Vaccine and Infectious Disease Division, Fred Hutchinson
Cancer Research Center, Seattle, WA, USA
J. Wang
Statistical Center for HIV/AIDS Research & Prevention
(SCHARP), Fred Hutchinson Cancer Research Center,
Seattle, WA, USA
D. W. Jones
Department of Clinical Research, London School of Hygiene
and Tropical Medicine, London, UK
D. W. Jones
Mwanza Intervention Trials Unit, National Institute
for Medical Research, Mwanza, Tanzania
123
AIDS Behav (2013) 17:3108–3119
DOI 10.1007/s10461-013-0542-9
limited or zero effectiveness of an investigational product
may be due to either the product’s lack of biological effi-
cacy or sub-optimal user adherence [8–10]. Moreover,
correlating the level of HIV protection to the level of
adherence might provide valuable insight into the rela-
tionship between a product’s pharmacokinetic properties
and its biologic activity [6, 11, 12]. Lastly, understanding
patterns and correlates of adherence can inform the design
of future prevention trials of similar interventions by pro-
viding realistic estimates of possible effect sizes based on
achievable levels of adherence.
Various methods have been used to gather information
on adherence in biomedical HIV prevention trials, includ-
ing self-report by face-to-face [3, 6, 13] or computer-
assisted [13] interview, participant diaries [14], drug dis-
pensing records [3], electronic monitoring of dosing [4],
drug levels in blood, urine or tissues [1, 3, 6] and biological
markers, such as HIV plasma viral load in studies of ARVs
to reduce HIV transmission [4]. The simplest and most
commonly used measure for quantifying adherence to HIV
prevention interventions has been to count unused study
product (for example, remaining pills in trials of oral PrEP
or unused applicators in microbicide trials) returned at
scheduled study visits.
A challenge to interpreting and comparing trial results is
the lack of standardization in defining, measuring, analys-
ing and reporting adherence for HIV prevention trials.
Trials often report simple summary measures of adherence,
with heterogeneity in calculation of these summary mea-
sures [15–18]. The absence of a common reporting stan-
dard undermines interpretation of adherence patterns,
product effectiveness, and predictors of adherence. Even
with seemingly simple methods such as pill counts,
adherence measurement is complex with issues concerning
how to handle visits when pills are not returned, apparent
‘over-adherence’ ([100 % of expected pills for the interval
between visits), missed visits (when product is thus not
dispensed for a period) and protocol-specified time off
treatment such as during pregnancy.
An additional challenge is the lack of a standardised
adherence terminology with clear definitions to designate the
same concepts across trials. Recent reviews have proposed a
new taxonomy for adherence research, with uniform terms
and definitions [19, 20]. ‘Adherence to medication’ describes
the participant’s use of the study product as prescribed.
Adherence has three components: initiation (the time point of
first dose), execution (the extent to which the participant’s
product use corresponds to the instructed regimen), and dis-
continuation (the time point when the participant stops using
the product). A fourth term, persistence, describes the length
of time between initiation and discontinuation.
We propose an additional term, adherence ‘coverage’, to
describe a participant’s tablet taking during the entire time
the participant is in a trial, including temporary treatment
interruptions. This is to recognise that, although the par-
ticipant may have been instructed to stop taking the drug
(and is thus taking the product as prescribed), these periods
should be included when reporting trial adherence.
Adherence coverage is arguably the most relevant measure
for interpreting trial results, as it provides an indication of
whether sufficient study medication was taken to expect a
biological response. We also propose the term ‘apparent
over-adherence’ to describe periods when counts of
returned study product suggest that the participant has taken
[100 % of expected doses.
In this paper, we use data from two recent biomedical
HIV prevention trials of herpes simplex virus type 2 (HSV-
2) suppression, which both dispensed pills to be taken
twice daily and used clinic-based pill counts of returned
study product to measure adherence, to demonstrate how
estimates of adherence vary depending on the assumptions
that are made in analysing and reporting adherence data. In
addition, we relate calculated adherence to biological
markers of pill activity (genital herpes reactivation), to
assess the value of pill counts as a measure of ‘true’
adherence.
Methods
We used data from two double blind, placebo-controlled
trials of daily HSV-2 suppressive therapy with acyclovir
for HIV prevention: one in Mwanza, Tanzania [21] and
HPTN 039, which was conducted in nine sites in Peru,
South Africa, United States, Zambia, and Zimbabwe[22]
(Table 1). Participants were randomised to twice daily
acyclovir 400 mg or matching placebo. In both trials, there
was no evidence of a difference in HIV incidence between
the acyclovir and placebo arms overall, whilst among the
sub-group with optimal adherence, those randomized to
acyclovir had decreased HSV-2 activity (genital ulcers or
HSV-2 DNA shedding) compared with those randomized
to placebo [21, 22]. There was no evidence that adherence
differed between randomization arms in either trial [22,
23]. In Mwanza, there was no evidence that participants
knew their randomization assignment [24]. In HPTN 039,
among the one-third of participants who thought that they
knew their randomisation assignment in an assessment
after the end of the study, a slightly higher proportion of
participants in the acyclovir arm than in placebo perceived
they were randomised to acyclovir [23].
Mwanza Trial
The Mwanza trial enrolled 1305 HSV-2 seropositive
women aged 16–35 years working in bars, guesthouses and
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Table 1 Summary of two herpes suppression trials for HIV prevention: Mwanza and HPTN 039
Mwanza trial HPTN 039
Study design
Location Tanzania Peru, South Africa, USA, Zambia,
Zimbabwe
Population HIV negative and HIV positive women HIV negative women and men who have
sex with men
Number randomised 1,305 3,277 (1395 women, 1882 men)
Length of follow up Up to 30 months Up to 18 months
Frequency of scheduled visits 3 monthly Monthly
Could resume tablets after treatment
interruption
Yes, but not for pregnancy or if
participant requested to stop taking the
drug
Yes
Main endpoints HIV incidence; genital and plasma HIV
RNA in HIV/HSV-2 co-infected women
HIV incidence; incidence of HSV-2
ulcers
Adherence measurement for main trial
publications
Medication dispensed Blister strips of 14 tablets each Bottles of 70
Identification numbers on bottles/
blister strips
Non-unique batch ID recorded when
dispensed only
Yes, unique ID recorded when dispensed
and returned
Amount of surplus tablets (‘buffer
stock’) supplied at each visit
2–3 weeks 5 days
Pill counts
Frequency Every visit Every visit
Performed by Dispensing clinician Dispensing clinician
Self report
Frequency Scheduled visits Every visit
Questions used If missed any tablets since last visit; if
missed C3 consecutive days of tablets;
total number of tablets missed
If missed any tablets since last visit; if
missed C2 consecutive doses;
maximum number of consecutive
missed doses
Adherence calculations
Handling of intervals with
adherence [100 %
Allowed 1–4 tablets overa; if [4 tablets
over, and did not report taking extra,
classed as missing
Allowed 5 % over; if [5 % over, classed
as missing
Handling of intervals when bottles/
blister strips not returned
Classified as missing Asked to return at next visit. If never
returned, used self report. If self-report
\100 %, classed as missing.
Returned pills matched to visit
dispensed
No, assumed to have been dispensed at
previous visit
Yes
Handling of intervals when
adherence classed as missing
Replaced as 70 % of expected tablets
taken, or all tablets dispensed,
whichever was less
Dropped from numerator and
denominator
Included periods off treatment Yes, except for pregnancy Yes
Summary measures used and
reported adherence
Median adherence = 90 %; person–years
with C90 % adherence = 52 %
(acyclovir arm) and 51 % (placebo)
Median % of expected doses
taken = 86 %; median % of dispensed
drug taken = 94 %; % of quarterly
visits with C90 % adherence = 73 %
Summary of data included in current
analysis
Total visits attended 9,199 48,446
Scheduled visits 9,139 47,551
Interim visits 60 895
Total visits analysed (i.e. excluding
visits after pregnancy)
8,149 47,243
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similar facilities in 19 communities in northwest Tanzania.
The trial enrolled both HIV negative (821) and HIV posi-
tive (484) women, to examine the effect of acyclovir on
HIV acquisition and among HIV-infected women, on HIV
genital shedding and viral load. Women were followed
every 3 months for 12–30 months. Women were with-
drawn permanently from the study medication if they
became pregnant, and study medication was withdrawn
temporarily for medical reasons such as intercurrent illness.
Women who were withdrawn from tablets continued to
attend follow-up visits, unless they requested to withdraw
completely from the trial.
At each quarterly visit, women were issued with a
supply of tablets to last until their next scheduled visit, plus
an additional 2–3 week buffer stock in case they were late.
Tablets were supplied in blister strips of 14 tablets. The
batch number was recorded when dispensed, but not when
returned. At each visit, women were asked to bring unused
tablets and empty blister strips from the preceding visit; the
number of remaining tablets was recorded by the
dispensing clinician. In addition to pill counts, women
were asked about self-reported adherence.
HPTN 039 Trial
The HPTN 039 trial enrolled 1,358 women and 1,814 men
who have sex with men who were HSV-2 seropositive and
HIV negative. Participants were followed monthly for
12–18 months with quarterly pregnancy and HIV testing.
Women with positive pregnancy tests were withdrawn
from study medication until pregnancy tests were negative,
and then tablets were resumed. Women who were with-
drawn from study medication continued to attend follow-
up.
At each visit, participants were issued with a supply of
tablets to last until their next visit, scheduled every
30 days, plus a 5-day buffer stock in case they were late.
Tablets were packaged in bottles of 70; each bottle had a
unique identification number that was recorded when dis-
pensed and returned. At each visit, participants were asked
Table 1 continued
Mwanza trial HPTN 039





972 (78 %) 2,428 (77 %)
Person–years of follow-up 2,144 4,081
Participants with treatment
interruption
233 (19 %)b; 14 (1 %)c 183 (6 %)b; 48 (2 %)c
Person–years off treatment 0.73c 13c
Visits with ‘measurable’
adherence
% visits with tablets
returned on time
95 %d 89 %
% visits with late/
unscheduled returns




% of all visits 2 % 4 %
% of participants ever 12 % 31 %
Apparent over-adherence
([105 %)
% of all visits 19 % 11 %
Median (IQR) tablets over 28 (16–46) 6 (4–10)
% of participants ever 66 % 65 %
a In the calculations of adherence summary measures for this paper (Methods 1 and 2), we allowed up to 5 % over-adherence in Mwanza instead
of 1-4 tablets over, for comparability with HPTN 039
b Participants with treatment interruptions for pregnancy (censored at pregnancy for adherence calculations)
c Participants with treatment interruptions not related to pregnancy
d In Mwanza, blister packs could not be matched to the visit at which they were dispensed because package numbers were not recorded at
returns; assume any tablets returned were dispensed at previous visit
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to return the bottle and unused tablets from the preceding
month, which were counted. If participants failed to return
a bottle, they were asked to return it at their subsequent
monthly visit and were instructed not to take any more
tablets from it. At each visit, participants were also asked
about self-reported adherence.
Adherence Calculations
We used pill count data from the Mwanza and HPTN 039 trials
to analyze adherence ‘coverage’, defined as tablet-taking
during the entire time the participant was in the trial, including
missed visits and temporary treatment interruptions.
For each participant, we calculated adherence at each
visit as [tablets issued at last visit - tablets returned]/[days
elapsed since last visit 9 2 (given the twice-daily use of
the study tablets)]. For HPTN 039, bottles that were
returned late were matched to the visit when they were
dispensed. In the Mwanza trial, blister strips could not be
matched to the visit when dispensed since that information
was not recorded; thus, all returned tablets were assumed to
have been dispensed at the previous visit. Adherence was
set to 0 during periods of treatment interruption. We
defined ‘optimal’ adherence as taking C90 % of expected
doses in the interval between visits.
For the Mwanza trial, since the primary analysis was
modified intent-to-treat that censored women at pregnancy,
for the adherence calculations, we excluded visits after
women were permanently withdrawn from tablets for preg-
nancy. In addition, for comparability with Mwanza, we cen-
sored women at pregnancy for the adherence calculations in
HPTN 039; although the primary intent-to-treat analysis
included periods off treatment for pregnancy. Thus, our esti-
mates of adherence coverage exclude visits after pregnancy.
Summary Measures to Describe Adherence During
the Trial
To describe average adherence coverage during the trial,
we used two summary measures commonly reported in
clinical trials to describe central tendency: overall study
adherence and median adherence. Overall study adherence
was calculated as [total tablets taken by all participants]/
[total days in study for all participants 9 2]. Median
adherence was calculated in two ways: (1) calculating
adherence at each visit for each participant, then computing
the median of per-visit adherence over all visits for all
participants; and (2) calculating overall adherence for each
participant, then computing the median of per-participant
adherence.
To describe optimal adherence, we used three measures
commonly reported in clinical trials: (1) the proportion of
visits with C90 % adherence; (2) the proportion of person–
years with C90 % adherence; and (3) the proportion of
participants with C90 % adherence during their entire
study participation, defined as [total tablets taken]/[total
days in study 9 2] C90 %.
Assessment of Missing Data and Over-Adherence
In trials that use pill counts to assess adherence, participants
are asked to return the pill containers (e.g. bottles, blister
packs) at each visit so that any remaining tablets can be
counted. The underlying assumption is that the remaining
tablets reflect the number that were dispensed at the previous
visit minus the number that were ingested by the participant.
However, generally there will be some visits when the
containers are not returned, or when fewer than the expected
number of tablets are remaining, and thus adherence is
calculated to be [100 % (‘apparent over-adherence’). To
calculate a summary measure of adherence, assumptions
must be made about the number of tablets taken for those
visits. We used two methods to explore the impact of these
assumptions on summary measures, drawing on methods
used by each trial in their primary publications.
Method 1 was based on the approach used in HPTN 039
[22], allowing adherence up to 105 % for each interval, due
to imprecision in being able to ascertain timing of last dose
with twice-daily dosing. If pill count data indicated
adherence was 100–105 %, we assumed the participant had
taken the tablets, and re-set adherence to 100 % for all
calculations. However, if pill count data indicated adher-
ence[105 %, or if tablets were not returned, we classified
adherence as ‘unknown’. Intervals with unknown adher-
ence were removed from the numerator and denominator
and excluded from the calculation of summary measures;
this approach assumes that the distribution of adherence in
intervals when it is unknown is similar to that when it is
known.
Method 2 was based on the approach used in the
Mwanza trial [21], also allowing up to 5 % over-adherence
(re-set to 100 % in calculations) but participants were
assumed to have low adherence (70 %) in intervals when
adherence was unknown (tablets not returned or adherence
[105 %). This approach assumes that intervals with
unknown adherence are likely to reflect periods of poor
adherence. As a sensitivity analysis, we explored the
impact of using a range of adherence levels, from 10 to
100 % (i.e. assuming that all pills were taken), during
periods when adherence was unknown.
Use of Biological Marker to Assess Periods
with Unknown Adherence
Within each adherence category, we examined the effect of
treatment arm on a biological outcome: for HPTN 039,
3112 AIDS Behav (2013) 17:3108–3119
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genital ulcer disease (GUD) with HSV-2 aetiology con-
firmed by HSV DNA PCR, based on quarterly genital
exams [22], and for Mwanza, genital HSV-2 DNA shed-
ding at the 6, 12 and 24 month visits, when samples were
collected [21]. Random-effects logistic regression was used
to estimate odds ratios (OR) for the association of treat-
ment with the detection of GUD or HSV-2 shedding at
each visit. Models contained fixed effects for treatment
arm, calculated adherence in the preceding interval, and
their interaction, and random effects for subject.
Results
We analysed 8,149 post-enrolment visits from 1,242 partici-
pants in the Mwanza trial and 47,243 visits from 3,140 par-
ticipants in HPTN 039 (Table 1). In Mwanza, 98 % of blister
packs were returned during the trial, and 95 % were returned at
the next 3-monthly visit. In HPTN 039, 96 % of bottles were
returned during the trial, 89 % at the next monthly visit.
In Mwanza, 247 (20 %) participants interrupted study
drug, including 233 who became pregnant and were per-
manently discontinued from study medication. In HPTN
039, 231 participants interrupted study drug, including 183
who became pregnant (14 % of all females). Time off
treatment for non-pregnancy related interruptions was 0.7
person–years in Mwanza and 13 person–years in HPTN 039.
Figure 1 shows the distribution of adherence at each
visit based on the actual pill count data. Two-thirds of
participants had C1 interval when calculated adherence was
[105 %, which accounted for 19 and 11 % of visits in
Mwanza and HPTN 039, respectively.
In Mwanza, where scheduled visits were quarterly, the
proportion of participants with adherence 90–105 % ran-
ged from a low of 46 % at the second visit (month 6) to a
high of 57 % at month 18 (Fig. 2). In HPTN 039, with
more frequent (monthly) visits, the proportion of partici-
pants with adherence 90–105 % ranged from a low of 64 %
at the first visit (month 1) to a high of 73 % at month 14.
In Mwanza, participants self-reported not missing any
doses in 19 % of intervals with pill count-based adherence
\75 %, 6 % of intervals with adherence 75–89 %, 52 % of
intervals with adherence 90–105 %, and 84 % of intervals
with unknown adherence. In HPTN 039, participants self-
reported not missing any doses in 38 % of intervals with
adherence \75 %, 43 % of intervals with adherence
75–89 %, 83 % of intervals with adherence 90–105 %, and
80 % of intervals with unknown adherence.
Summary Measures of Adherence
Estimates of average adherence coverage during the trials
ranged from 82–98 % in Mwanza, and 88–100 % in HPTN
039, depending on the summary measure and the method used
to calculate it (Table 2). Estimates of overall adherence were
lower than those of median adherence. Adherence appeared
highest when the median per-visit adherence was used;
excluding unknown intervals, rather than considering them as
periods of poor adherence, made adherence appear higher for
all measures. Calculating the median as a per-participant
measure gave an impression of lower adherence than calcu-
lating median adherence as a per-visit measure. Since median
per-visit adherence is based on data at all visits, participants
who attend more visits will contribute more information. In
contrast, for median per-participant adherence, the data are
first aggregated by participant, so all participants contribute
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Pills not returned 2.2%
Fig. 1 Estimated adherence at each visit in Mwanza (top) and HPTN
039 (bottom) trials among all participants (including treatment
interruptions. In Mwanza, women were permanently withdrawn from
study medication if pregnant, but continued with followup; the
primary analysis was modified intent-to-treat that censored women at
pregnancy. Therefore, for the adherence calculations, visits after
women were withdrawn for pregnancy are excluded. In HPTN 039,
women were temporarily withdrawn until pregnancy tests were
negative, and then tablets were resumed; the primary analysis
included periods off treatment for pregnancy. However, for compa-
rability with Mwanza, visits after women were withdrawn for
pregnancy are excluded from the adherence calculations and missed
visits)
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Estimates of optimal adherence (C90 %) ranged from
27–71 % in Mwanza and 56–84 % in HPTN 039,
depending on the method used and whether data were first
aggregated by participant before the measure was
calculated. Optimal adherence appeared highest when the
proportion of visits with adherence C90 % was used, and
unknown intervals were excluded. In contrast, reporting the


























































<75% 75-89% 90-100% 100-105% >105% Not returned
Fig. 2 Adherence in HPTN 039
and Mwanza trials by pill counts
at selected scheduled visits.
Adherence in HPTN 039 shown
at visits every 3 months, for the
preceding month, to show data
for each trial at comparable
points in follow-up time
Table 2 Commonly reported summary measures of adherence, with different assumptions regarding intervals with unknown adherence owing to
missing tablet counts and apparent over-adherence ([100 %)












10 % 30 % 50 % 100 % 10 % 30 % 50 % 100 %
Measures of ‘average’ adherence coverage
Median per-visit adherenced 95 % 90 % 90 % 90 % 90 % 98 % 99 % 97 % 97 % 97 % 97 % 100 %
Median per-participant
adherencee
89 % 83 % 70 % 74 % 79 % 91 % 95 % 91 % 84 % 86 % 89 % 96 %
Overall adherencef 86 % 82 % 71 % 75 % 79 % 88 % 92 % 88 % 80 % 82 % 85 % 91 %
Measures of ‘optimal’ adherence coverage
Proportion of visits with
adherence C90 %
64 % 51 % 51 % 51 % 51 % 71 % 82 % 70 % 70 % 70 % 70 % 84 %
Proportion of person years
with adherence C90 %
61 % 48 % 48 % 48 % 48 % 69 % 79 % 67 % 67 % 67 % 67 % 82 %
Proportion of participants
with C90 % adherenceg
48 % 27 % 18 % 19 % 21 % 56 % 73 % 54 % 34 % 39 % 45 % 74 %
a Unknown excluded: allow up to 105 % adherence (re-set to 100 %), otherwise unknown; exclude intervals with unknown adherence from
numerator and denominator (Method 1)
b Unknown replaced as 70 %: allow up to 105 % adherence (re-set to 100 %), otherwise unknown; assume adherence in unknown intervals is
low (70 %) (Method 2)
c Sensitivity analysis using a range of adherence levels to replace intervals when adherence is unknown
d Adherence calculated at each visit for each participant as (tablets taken since last visit/days elapsed since last visit 9 2), then median taken
over all visits and participants
e Adherence calculated overall for each participant as (total tables taken/total days in study 9 2), then median taken over all participants
f Total tablets taken by all participants/total days in study for all participants 9 2
g Adherence for each participant calculated as (total tablets taken during study/total days in study 9 2)
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unknown intervals assumed to represent poor adherence,
gave the most pessimistic picture of optimal adherence.
In both trials, participants who attended more visits had
higher adherence. In Mwanza, participants’ overall adher-
ence during the trial was on average 2.4 % higher for each
one-visit increase in total visits attended. In HPTN 039,
participants’ overall adherence was 1.6 % higher for each
one-visit increase in total visits attended. Therefore, per-
visit measures gave a better reflection of average and
optimal adherence than per-participant measures.
Impact of Assumptions Made About Missing Data
and Over-Adherence on Summary Measures
Assumptions made about how to handle intervals with
unknown adherence (excluding or replacing as low
adherence) had a larger impact on measures of optimal
adherence than on measures of average adherence. Since
optimal adherence is based on the proportion of data
above a fixed cut-off (C90 %), decisions about the
unknown intervals affect the denominator but not the
numerator. For example, when unknown adherence was
assumed to be low (B70 %), only 48 % of person–years
in Mwanza had adherence C90 %, compared with 61 % if
unknown intervals were excluded from the calculation. In
contrast, median per-visit adherence in Mwanza was
similar if we assumed that adherence was low in unknown
intervals or if we excluded these intervals (90 vs 95 %
respectively).
The relative difference between optimal adherence
obtained by the two methods of handling unknown inter-
vals increased with the amount of missing data. Mwanza
had a higher proportion of visits with unknown adherence
than HPTN 039 (21 vs 15 %); therefore, the choice of
method for handling unknown intervals had a larger impact
on calculations of optimal adherence in Mwanza.
When we assumed adherence was low (B70 %) in
unknown intervals, most measures of optimal adherence,
and median per-visit adherence, were not changed by the
value assigned to the unknown intervals. In contrast,
overall adherence, and median per-participant adherence,
were sensitive to the value assigned, and the relative dif-
ference between the two methods of handling unknown
intervals became larger as lower values were used. The
proportion of participants with adherence C90 % was most
sensitive to the value assigned to unknown intervals, with
only 45 % of participants in HPTN 039 having optimal
adherence if we assumed adherence was 50 % in unknown
intervals, versus 54 % if we assumed adherence was 70 %
in unknown intervals. At the other extreme, if we assumed
adherence to be 100 % in unknown intervals, then 74 % of
participants had optimal adherence. Thus, the proportion of
visits with missing data and assumptions about adherence
in those intervals can have a large influence on adherence
estimates.
Relationship Between Calculated Adherence
and Biologic Measures of Study Product
In Mwanza, genital HSV-2 DNA shedding was detected at
176 (8 %) of 2,198 visits. In HPTN 039, HSV-2 PCR
positive GUD was detected at 891 (5 %) of 18,945 visits.
The association of acyclovir with reduction in genital
HSV-2 shedding (Mwanza) and incident GUD (HPTN 039)
was greater among participants with calculated adherence
90–105 % in the preceding interval, than among partici-
pants with calculated adherence \90 % or [105 %, or
participants in whom adherence could not be calculated
because tablets were not returned (Fig. 3).
Discussion
Interpretation of efficacy in trials of user-dependent HIV
prevention strategies requires clear and consistent methods
for measuring and reporting adherence to study product. Our
results show that calculated adherence based on pill counts
varies substantially, depending on the assumptions made
about how to handle missing and inaccurate data and the
choice of summary measure, and can provide substantially
different impressions of product use. Recent HIV prevention
trials have reported adherence to study product of 90 % or
higher based on pill counts [3, 4, 7]. However, such esti-
mates may provide a simplistic or overly high indicator of
adherence. Our analysis depicts a considerably more
nuanced picture of adherence and emphasizes the need for
more standardised approaches to reporting adherence data in
order to facilitate interpretation of trial results and compar-
isons across trials of similar interventions.
Both HPTN 039 and Mwanza reported median adher-
ence [90 % in their main trial publications [21, 22], but
used different assumptions in their calculations so the
measures were not comparable. We found that, when cal-
culated in the same way with the same defined exclusion
periods, median and overall adherence were very similar in
both trials. However, measures of optimal adherence were
substantially higher in HPTN 039, suggesting much higher
levels of actual product use. The lack of an overall effect
on biological markers of genital herpes reactivation, as
reported in Mwanza [21], despite very high median
adherence, shows that median adherence may not provide a
very useful indicator of total study drug exposure during a
trial. Summaries of optimal adherence, such as the pro-
portion of person–years with adherence C90 %, may give a
better reflection of actual product use, but are more sen-
sitive to assumptions made about intervals with unknown
AIDS Behav (2013) 17:3108–3119 3115
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adherence, particularly when the amount of missing data is
large. Another disadvantage of measures of optimal
adherence is that they dichotomise participants based on a
fixed threshold value believed to represent sufficient drug
exposure to achieve a therapeutic result; however, in
practice, there are a range of factors that determine the
threshold that is needed for a satisfactory treatment effect.
Furthermore, as a review of adherence measurement points
out, adherence in the 90–100 % range is generally con-
sidered ‘good’, but this figure is not inconsistent with
multi-day lapses in dosing during which drug concentra-
tions fall below therapeutic levels, particularly with drugs
with a short half-life like acyclovir [25].
Adherence in a particular interval can be unknown for
several reasons: the participant may fail to return the tablets
(missing data), calculated adherence may be[100 %, or the
tablets may be returned late, so a participant is issued with a
new set of tablets before returning the first set. In Mwanza,
we could not link tablets to the visit dispensed, so we
assumed that all tablets returned were issued at the previous
visit. In HPTN 039, a unique bottle identification number
was recorded when tablets were dispensed and returned, so
we were able to match the bottles to the visit dispensed.
Thus, unique study product identifiers may offer important
advantages for assessing the ‘measurability’ of adherence in
a trial. In addition, shorter times between visits may help
reduce errors by reducing the amount of surplus tablets
issued and allowing adherence messages to be reinforced
more frequently. Mwanza had longer intervals between
visits and was of longer duration than HPTN 039, which
may have resulted in more intervals with unknown adher-
ence. The proportion of visits with unknown adherence is a
key factor influencing adherence estimates, and should be a
greater focus in implementation of future trials and critiqued
carefully when trials report their results.
In both trials, although the biological markers of genital
herpes reactivation were different (PCR confirmed GUD in
HPTN 039 and HSV-2 shedding ascertained at 3 time
points in Mwanza), we found that the effect of acyclovir on
biologic measures of anti-HSV-2 activity was similar
among participants with pill counts that suggested adher-
ence[105 % and those with adherence \90 %, and lower
than those with 90–105 % adherence. This is consistent
with recently-reported findings from the Partners in Pre-
vention HSV/HIV Transmission Study, in which low and
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Mwanza HPTN 039 
N with HSV - 2 DNA / total (%) N with HSV - 2 GUD / total (%) 
Acyclovir Placebo Acyclovir Placebo
Off treatmenta
<75-89% 
149 / 6199 (2.4 %) 
Not returned 
11 / 114 (9.6 %) 7 / 98 (7.1 %)
<75% 11 / 90 (12.2 %) 9 / 102 (8.8 %)
15 / 158 (9.5 %) 11 / 181(6.1 %) 
90–105% 27 / 518 (5.2 %) 40 / 493 (8.1 %)
>105% 18 / 204 (8.8 %) 15 / 191(7.9 %) 
7 / 27 (25.9 %) 5 / 22 (22.7 %)
14 / 175 (8.0 %) 13 / 182 (7.1 %) 
13 / 525(2.5 %) 31 / 536(5.8 %)
17 / 821 (2.1 %) 53 / 935 (5.7 %) 
463 / 6598 (7.0 %)
39 / 1018 (3.7 %) 68 / 1051 (6.5 %)
14 / 463 (3.0 %) 18 / 442 (4.1 %) 
a Intervals when drug was not dispensed, including treatment interruptions for pregnancy 
Fig. 3 Log OR and 95 % confidence interval of genital HSV-2 DNA shedding (Mwanza, left) or in genital ulcer disease (GUD) of HSV-2
aetiology (HPTN 039, right), comparing acyclovir with placebo, within each pill count adherence category
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infected persons was associated with a reduced effect on
HIV-1 plasma viral load and HSV-2 GUD [26]. Acyclovir
suppression significantly but incompletely reduces symp-
tomatic genital ulcers and HSV-2 shedding, so both are
imperfect markers of adherence and drug exposure [27].
However, since clinical effects such as genital ulcers are
determined by adherence over a period of time, the inci-
dence of GUD in HPTN 039 and HSV-2 shedding in
Mwanza may provide a clinical measure of acyclovir
exposure in these trials. Our findings suggest that partici-
pants with tablet counts indicating over-adherence are not
actually taking the tablets; similar findings have been
reported from studies of hypertension [28] and anti-obesity
medication [29], and a study that used phenobarbital as a
chemical marker of adherence [30]. Thus, when calculating
summary measures, it may be better to assume that inter-
vals with apparent over-adherence represent periods of low
adherence, rather than excluding them or considering them
as if they reflect 100 % adherence. Reporting the propor-
tion of visits with apparent over-adherence may provide
important information about actual product use.
Although tablet counts suggesting over-adherence beyond
a certain cut-off (e.g., 105 %) could represent pill dumping
by participants to improve their apparent adherence, some
shortfall in the number of tablets returned should be allowed,
to account for the occasional dropped tablet or imprecision in
accounting for tablets that were taken on the day dispensed
and returned. There could also be some genuine over-
adherence, for example, if the participant forgets she or he has
taken a tablet and takes an extra one. Using a fixed number of
tablets to define over-adherence, rather than a percentage,
could be a more reasonable approach, particularly with longer
intervals between visits.
In addition to potential bias from intervals with unknown
adherence, the choice of summary measure used to report
trial adherence can provide a misleading estimate of product
use. As our results demonstrate, reporting the median, either
per-visit or per-participant, to summarise trial adherence can
obscure a large number of subjects with poor adherence. In
both trials, participants who attended more visits were in the
trial for longer and had better adherence than those who
attended less frequently. Thus summary measures that gave
equal weight to the participants who dropped out early and
those who remained in the trial provided an impression of
lower adherence than measures that were weighted by the
number of visits attended. This further highlights the need
for a standardisation in calculating and reporting summary
measures.
In both trials, we found that adherence based on self-
report of number of missed doses was higher than that
based on pill counts. We did not use self-report in our
adherence calculations for this paper; however, self-report
was used to supplement the pill counts in the adherence
calculations for the main trial papers. The tendency of self-
report to overestimate adherence, when compared with pill
counts [3, 6], electronic monitoring devices [31] or drug
detection [2, 6, 32] methods has been cited by other stud-
ies. Although asking participants about the number of
missed pills may be of limited utility, other methods of
self-evaluation, such as qualitative rating scales, may pro-
vide more reliable information [33].
Strengths of our study include analyses of data from two
large HIV prevention efficacy trials of acyclovir suppres-
sion, with the same intervention but different visit schedules
and different procedures for performing tablet counts. This
allowed us to examine the impact of different study proce-
dures and analysis assumptions on reported measures of
adherence. Limitations of our study include that pill counts
of returned study product are an imperfect method of
assessing adherence, and did not allow us to assess finer
patterns of adherence, for example, as would be possible
with electronic daily monitoring. A further limitation is that
clinic-based pill counts have been found to overestimate
adherence compared with electronic monitoring [34, 35] or
drug levels [6], and are subject to manipulation, as partici-
pants may discard unused pills to create an illusion of good
adherence. The validity of pill counts to assess adherence
relies on the assumption that unreturned tablets were
ingested by the participant; however, estimates of adherence
may be severely biased if unreturned tablets do not reflect
actual product use. An additional limitation is that pill
counts were done at every visit; however, GUD and HSV-2
shedding were measured less frequently. Although we had
some clinical indicators of adherence, the half-life of acy-
clovir is *3 h with minimal accumulation [36], thus lim-
iting acyclovir drug levels as a gold standard for evaluating
our adherence measures using pill counts. Lastly, the
Mwanza trial and the majority of the HPTN 039 sites were in
resource-limited settings; therefore, our finding that pill
counts suggestive of over-adherence are likely to represent
pill dumping may not be generalisable to other settings.
Our results have demonstrated that there is a clear need
for standardisation in adherence reporting. The CONSORT
statement was developed to provide a set of guidelines for
the clear, complete and transparent reporting of results
from randomised controlled trials [37–39]. Although these
guidelines implicitly recognise the importance of adher-
ence in interpreting trial results, there are no recommen-
dations for how to report adherence. For clinic-based pill
counts of unused study product, authors should report the
proportion of visits in which tablets were not returned, or
where pill counts found adherence to be[100 %, and how
intervals with unknown adherence were handled in calcu-
lation of summary measures. To provide a measure of
uncertainty of these adherence metrics, it is useful to report
the summary measures using different assumptions
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(e.g. excluding unknown intervals and considering these as
low adherence). We recommend that trials should report
measures of study medication adherence coverage (i.e.
including missed visits and time off treatment), as the most
relevant measure for understanding results from the intent-
to-treat analysis. Although all summary measures provide
an imperfect assessment of adherence, overall adherence,
since it takes into account the total days that each partici-
pant is in the trial, may provide a reasonable reflection of
drug exposure on average over the duration of the trial.
Some estimate of the amount of person–time with optimal
adherence may be useful, since this relates exposure to
levels needed to achieve a biological effect. However, in
addition to the problems of dichotomising adherence as
discussed above, there can be difficulties in operationalis-
ing ‘optimal’ adherence: the definition is likely to differ
between study drugs, formulations and dosing regimens
(and may not be known for new investigational products),
creating further complications for standardising definitions
across trials. Summary measures of median adherence,
either per-visit or per-participant, are not particularly
informative.
In summary, we have shown that summary measures of
adherence in two recent HIV prevention trials of acyclovir
varied considerably depending on assumptions and analysis
method. Our findings of a relationship between adherence
and clinical markers (GUD or HSV-2 genital shedding)
indicate that intervals of apparent over-adherence are likely
to represent pill-dumping. Thus, the proportion of visits
with unknown adherence, either because tablets are not
returned or calculated adherence is too high, may provide
important information. The impact of the assumptions
made on calculated measures indicate the important need
for standardisation of best practices in adherence reporting,
to aid in the interpretation and understanding of user-
dependent HIV prevention interventions.
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